Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "David-Hyman"

1 News Found

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer
News | October 26, 2023

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer

In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)